Drug Trial Radar · NCT07057427
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
812
Planned (sponsor's estimate)
Start
Jun 24, 2025
Primary completion
Jun 30, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Henan Cancer HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Jul 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the efficacy of nab-paclitaxel (on days 1 and 8 of a 21-day cycle) compared to the standard regimen of docetaxel plus carboplatin, both combined with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.
Conditions
- Breast Cancer
Interventions
Nab paclitaxelDrug
Nab-paclitaxel (on days 1 and 8 of a 21-day cycle)
Docetaxel and CarboplatinDrug
Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1)
Trastuzumab + PertuzumabDrug
Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and pertuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological Complete Response (pCR)Time frame: through study completion, up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan cancer hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.